Analysis of the Prevalence of Socially Significant Non-communicable Diseases in the Russian Federation at the Present Stage
DOI:
https://doi.org/10.61841/0smg5469Keywords:
Socially Significant Diseases, Risk Factors, Preventive Medical Examination, Formation of a Healthy LifestyleAbstract
Socially significant diseases represent enormous damage to society associated with high morbidity, temporary disability, disability, and mortality. An integrated approach to the treatment of patients with this group of diseases requires huge costs for diagnosis, rehabilitation, prevention of premature mortality, and social support for patients, as well as preventive measures against crime (drug and alcohol abuse). The aim of the study was to analyze the epidemiological situation on the prevalence of socially significant noncommunicable diseases. The methods of analytical processing of official statistics (www.Gsk.ru) were used in the present study. It is established that the priority solution to the problem of social diseases is the prevention of risk factors of their development with the implementation of modern technologies of prevention. This will allow for purposeful and successful use of economic and medical resources for primary prevention of socially significant diseases and improvement of the population.
Downloads
References
[1] Decree of the RF Government dated 28.12.2012 № 1472 «Amendments to the federal target-oriented program ―Prevention and treatment of socially significant diseases‖ (2007—2012). М.; 2012.
[2] World Health Organization, World Bank. World Report on Disability. Geneva: WHO; 2011.
[3] Lisitsyn Y.P. Public health and healthcare. Handbook. М.: GEOTAR-MED; 2002: 44-68.
[4] Oganov R.G. National clinical guidelines. 2nd edition. M.: Silitsea-Polygrap”h; 2009.
[5] Oganov R.G., Timofeeva T.N., Koltunov I.E. et al. Epidemiology of arterial hypertension in Russia. Results of federal monitoring in 2003–2010. Cardiovascular therapy and prevention. 2011; 10 (1): 8-12.
[6] European Society of Cardiology. CVD Prevention in Clinical Practice (European Guidelines on). 2007.
[7] Morbidity rate of the population in Russia in 2011 (statistical materials). Ministry of Healthcare of the Russian Federation, Department of the analysis, prognosis, development of healthcare and medical science,
Federal Central Scientific and Research institute of the organization and IT support of the Ministry of the
Russian Federation. М.; 2012; p. 1, 3, 5.
[8] Suhrcke M., Rocco L., McKee M. et al. On behalf of the European Observatory on Health Systems and
Policies. Economic consequences of noncommunicable diseases and injuries in the Russian Federation.
WHO, 2007: 89.
[9] Dedov I.I., Shestakova M.V. Diabetes mellitus and arterial hypertension. М.: MIA; 2006: 320-9.
[10] Radermecker R.P., Philips J.C., Jandrain B., Paquot N., Scheen A.J. Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE, and VA-Diabetes trials. Rev. Med. Liege. 2008; 63 (7-8): 511-8.
[11] Report on the condition of healthcare in Europe, 2009. Health and systems of healthcare. Copenhagen, WHO; 2010.
[12] Marinicheva G.N., Lukevich V.S., Grigorieva N.O. The study of peculiarities of social-genetic functioning and risk factors that influence the health and quality of life of the population. Fundamental studies. 2011; 12:794-802.
[13] Socially significant diseases in Russia in 2011. Statistical data. Ministry of Healthcare of the Russian
Federation, Department of the analysis, prognosis, development of healthcare and medical science, Federal
Central Scientific and Research institute of the organization and IT support of the Ministry of the Russian
Federation. М.; 2012.
[14] Kalabekov I.G. Russian reforms in figures and facts (reference book). М.: Rusaki; 2007.
[15] Federal service on surveillance in the sphere of consumer rights protection and welfare. Federal center of
hygiene and epidemiology. Data on infectious and parasitic diseases. December 2018.
https://rospotrebnadzor.ru/activities/statistical materials/statictic_details.php?ELEMENT_ID=11277 (date
of request: March 30th, 2019).
[16] Federal service on surveillance in the sphere of consumer rights protection and welfare. Federal center of
hygiene and epidemiology. Data on infectious and parasitic diseases. January-December 2018.
https://rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=11277 (date
of request: March 30th, 2019).
[17] Bloom, David E., David Canning, and Gaypee Sevilla. The demographic dividend: a new perspective on the
economic consequences of population change. Santa Monica, California: RAND, MR–1274, 2003.347.
[18] Bloom David E., David Canning, and Bryan Graham. Longevity and life-cycle savings. Scandinavian
Journal of Economics. – 2003. – Vol. 105. –September. – Pp. 319-338.348.
[19] Bourdieu P. Distinction: a social critique of the judgement of taste / translated by R. Nice. – Cambridge:
Harvard University Press, 1984.—613 p. 349.
[20] Bourdieu P. The forms of capital / A. Halsey, H. Lauder, P. Brown, and A. Wells, eds. // Education, culture, economy, and society. – Oxford: Oxford University Press, 2002. – Pp. 46-58.
[21] Dummond M. Standardizing Methodologies for Economic Evaluation in Health Care / M. Dummond, A. Brandt // International Journal of Technology Assessment in Health Care. — 1998 — № 9(1) — Р. 26–36.
[22] Murray CJL, Lopez A.D., The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press on behalf of the World Health Organization and the World Bank, 1996.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.